Market revenue in 2020 | USD 33.1 million |
Market revenue in 2028 | USD 72.6 million |
Growth rate | 10.3% (CAGR from 2020 to 2028) |
Largest segment | Neurological disorders |
Fastest growing segment | Cancer |
Historical data | 2016 - 2019 |
Base year | 2020 |
Forecast period | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Neurological Disorders, Immunological Disorders, Hematology Diseases, Endocrine & Metabolism Diseases, Cancer, Musculoskeletal Disorders, Cardiovascular Disorders, Dermatology Disease |
Key market players worldwide | Quest Diagnostics Inc, Centogene NV Ordinary Shares, Invitae Corp, Eurofins Scientific SE, PerkinElmer, Macrogenics Inc, Fulgent Genetics Inc, Myriad Genetics Inc, Labcorp Holdings Inc, OPKO Health Inc, 3billion, ARUP Laboratories, Strand Life Sciences, Ambry Genetics, REALM IDx, Inc., Baylor Genetics, Health Network Laboratories, PreventionGenetics, Biora Therapeutics, CooperSurgical, Artemis DNA |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rare disease genetic testing market will help companies and investors design strategic landscapes.
Neurological disorders was the largest segment with a revenue share of 16.01% in 2020. Horizon Databook has segmented the Japan rare disease genetic testing market based on neurological disorders, immunological disorders, hematology diseases, endocrine & metabolism diseases, cancer, musculoskeletal disorders, cardiovascular disorders, dermatology disease covering the revenue growth of each sub-segment from 2016 to 2028.
Initiatives undertaken in the country pertaining to rare disease diagnosis over the past years has driven the revenue growth Japan market. For instance, In 2015, the Japan Medical and Research Development Agency (AMED) has launched the Initiative on Rare and Undiagnosed Disease (IRUD) as a clinical research program for people living with rare diseases.
AMED is a nation-wide research group that aimed at promoting the diagnosis of patients with rare disease via data sharing. In addition, ongoing conferences that aimed at supporting rare disease management via addressing the challenges is expected to positively impact the revenue growth in the country.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan rare disease genetic testing market , including forecasts for subscribers. This country databook contains high-level insights into Japan rare disease genetic testing market from 2016 to 2028, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account